Armata Pharmaceuticals Reports $173.8 Million Net Loss and Advances Clinical Trials in Latest 10-K Filing

Armata Pharmaceuticals, Inc. has reported significant financial developments in its latest 10-K filing for the fiscal year ending December 31, 2025. The company, which specializes in developing bacteriophage therapeutics to combat antibiotic-resistant infections, recorded a net loss of $173.8 million, a substantial increase from the $18.9 million loss reported in the previous year. This increase in losses is attributed to a notable change in the fair value of the company's Convertible Loan, which resulted in a loss of $121 million, alongside rising interest expenses totaling $16.6 million.

In terms of revenue, Armata generated $4.9 million in grant and award revenue, a slight decrease from $5.2 million in 2024. The company’s operating expenses also saw a decline, totaling $41.5 million compared to $47.6 million in the prior year, primarily due to reduced research and development costs, which fell by 31.1% to $23.7 million. This reduction reflects the winding down of clinical trial activities for its product candidates, particularly AP-PA02 and AP-SA02.

Strategically, Armata has made significant strides in its clinical development pipeline. The company has completed three Phase 2 clinical trials for its lead product candidates, AP-PA02 and AP-SA02, which target chronic pulmonary infections and complicated bacteremia, respectively. The positive results from these trials have positioned Armata to advance to Phase 3 trials, with the AP-SA02 study expected to begin in the second half of 2026. Additionally, the company has received a total of $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium, which supports its ongoing clinical programs.

Operationally, Armata has improved its manufacturing processes, enhancing the purity and potency of its bacteriophage products. As of December 31, 2025, the company employed 61 full-time staff, with a focus on research and development. However, the company faces challenges related to its financial condition, as it reported an accumulated deficit of $501.5 million and indicated that its existing cash reserves of $8.7 million would not be sufficient to fund operations for the next 12 months. This raises substantial doubt about its ability to continue as a going concern without securing additional financing.

Looking ahead, Armata's management is actively exploring various funding options, including public and private equity offerings, debt financing, and strategic collaborations. The company acknowledges that its ability to raise additional capital may be adversely affected by global economic conditions and market volatility. Despite these challenges, Armata remains committed to advancing its innovative bacteriophage therapies as potential alternatives to traditional antibiotics, addressing the urgent need for effective treatments against drug-resistant bacterial infections.